Obermatt

Krka

LJU:KRKG · SI0031102120
PharmaceuticalsLarge

360

63
EV / EBIT54
Price / Owner Earnings63
Owner Earnings Yield75
Dividend Yield89
Price/Sales47
EV / Gross Profit49
Price/Book43
Return on Capital77
Cash Return on Capital62
Return on Equity57
EBIT Margin63
Gross Profitability47
Cash Conversion49
Accruals40
Owner Earnings Margin65
Sales growth45
Profit Growth64
Long-Term EPS Growth18
Owner Earnings Growth27
Reinvestment87
Price momentum72
Debt load93
Refinancing86
Debt Payback100
Liquidity84
Analyst ratings18
Opinion Changes50
Price Target Upside4
Market mood77
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Krka generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountrySlovenia
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeLJSE
Founded1989
Employees2,838
Websitekrka.si
ISINSI0031102120
Last UpdateApr 2, 2026
Index & Theme
DiabetesCardiovascularPain ManagementCentral Nervous SystemMedicalPharmaceutical

Description

Analysis

Middle-of-the-road

Krka, d. d. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is fair. You pay 20.9× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 7% yearly growth; analysts expect 4%. The price, in other words, assumes less than the experts do.

The trajectory is tepid and the balance sheet is sturdy. The company scores 14/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
98
2023202420252026

All-time high

100

Mar 2026

All-time low

98

Jun 2026

Average rank

99

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
47
26
48
58
Price/Earnings
20
34
67
66
Price/Book
43
35
57
67
Dividend Yield
89
96
100
100
Value (overall)
61
52
83
82

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Krka with its peers
Vetoquinol
PAR:VETO
76
CountryFrance
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Euroapi
PAR:EAPI
37
CountryFrance
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Haleon
LSE:HLN
31
CountryUK
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Novartis
VTX:NOVN
38
CountrySwitzerland
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
AstraZeneca
LSE:AZN
67
CountryUK
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Virbac
PAR:VIRP
58
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →